| In Vivo | ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days)
treatment significantly reduces the tumor volume in the Calu-6 human
NSCLC subcutaneous tumor xenograft model in mice[1]. Animal Model:
Calu-6 NSCLC xenograft tumor models in mice[1]. Dosage: 50, 75 mg/kg.
Administration: Orally either daily (qd) or every other day (q2d) for 27
days. Result: Significantly reduced the tumor volume. |
|---|
